Program Leaders

Gudkov博士、Adjei博士和Walker先生这3位新的高级领导人为 以及丰富的科研项目开发、行政领导经验 从他们参与NCI指定的其他主要癌症项目中获得(病例综合 癌症中心、梅奥诊所癌症中心和俄亥俄州立大学综合癌症中心， )。 每一位高级领导也在CCSG计划或共享资源中发挥着关键作用。阿德吉博士 担任分子靶标和实验治疗(MTET)的负责人并监督临床 研究服务部，古德科夫博士是细胞应激和生物物理疗法(CSBT)计划的负责人， 詹姆斯·马歇尔博士领导癌症预防和人口科学(CPPS)项目。坎迪斯博士 约翰逊是前列腺计划和MTET的积极参与者，而特朗普博士参与了 分子靶标和实验治疗计划。沃克先生担任CCSG管理员 并监督CCSG共享资源。高级领导团队的所有成员都积极参与 教师招聘流程，担任搜索委员会的主席或成员。更远的是，他们还 参与协调EAB会议、年度务虚会、座谈会/研讨会系列，并参与 发展活动。这些领导人中的每一位都活跃在国家癌症研究论坛上， 融入这些外部领域的领导和委员会职位(ASCO、AACR、AACI、NCCN、NCI [caBIG、IRGS、家长委员会])确保他们了解并参与关于 在癌症研究、护理和教育方面的重要国家主题，并保证RPCI意识和 引领全国潮流。 高级领导团队每天进行非正式互动，并每周在 主要行政领导论坛，即RPCI执行理事会。由特朗普博士主持的 执行委员会是学会的主要决策机构，负责持续监督 RPCI并解决其成员提出的所有职能问题。此外，高级领导层 参与CCSG指导委员会，这是一个每月开会的委员会，包括研究 项目负责人以及重要的CCSG和研究所计划的负责人[例如，成像开发、 健康差距]。由特朗普博士担任主席的CCSG指导委员会为战略会议提供了场所 规划、计划评估、成员审查和批准以及对现有和拟议共享的审查 资源。尽管高级领导层还有其他几个参与的场所，但它是通过 这两个委员会认为初步决策是完成的。 在上一个供资周期中，区域合作伙伴关系有了显著的增长。在这个筹资周期内(2002至2006) 高层领导团队通力合作，招募了100多名癌症研究人员和临床医生， 将NCI资金增加74%，增加治疗研究人员发起的临床试验的应计收益，并增加 门诊量在这段时间内增加了42%。随着以癌症为重点的基础、翻译、 RPCI的临床和人口调查人员有所增长，四个新的共享资源 成立的目的是支持成员国的需要，目前还有三个正在开发中。预计 目前的高级领导团队将通过制定和执行长期计划来继续这一成功的轨迹 研究所的愿景和战略规划。

The 3 new senior leaders, Dr. Gudkov, Dr. Adjei, and Mr. Walker, bring fresh ideas and perspectives to the Institute as well as a wealth of scientific program development, and administrative leadership experience garnered from their involvement at other major NCI-designated cancer programs (Case Comprehensive Cancer Center, Mayo Clinic Cancer Center and the Ohio State University Comprehensive Cancer Center, respectively). Each of the Senior Leaders also plays a pivotal role in a CCSG Programs or Shared Resources. Dr. Adjei serves as Leader of the Molecular Targets and Experimental Therapeutics (MTET) and oversees Clinical Research Services, Dr. Gudkov is Leader of the Cell Stress and Biophysical Therapies (CSBT) Program, and Dr. James Marshall leads the Cancer Prevention and Population Sciences (CPPS) program. Dr. Candace Johnson is an active participant in the Prostate Program and MTET, while Dr. Trump participates in the Molecular Targets and Experimental Therapeutics Program. Mr. Walker serves as the CCSG Administrator and oversees the CCSG shared resources. All members of the Senior Leadership Team are active in the faculty recruitment process, serving as chairs or members of search committees. Further they are also involved in coordinating the EAB meetings, annual retreats, symposia/seminar series and participating in development activities. Each of these leaders is also active in national cancer research forums and well integrated into leadership and committee positions in these external arenas (ASCO, AACR, AACI, NCCN, NCI [caBIG, IRGs, parent committees]) assuring their awareness of and participation in deliberations regarding important national topics in cancer research, care and education and guaranteeing RPCI awareness of and leadership in the national trends. The Senior Leadership team interacts informally on a daily basis and meets formally on a weekly basis in the primary administrative leadership forum known as the RPCI Executive Council. Chaired by Dr. Trump, the Executive Council is the major decision-making body of the Institute, responsible for the on-going oversight of the RPCI and addressing all functional issues raised by its members. In addition, the Senior Leadership participates on the CCSG Steering Committee, a committee that meets monthly and includes the research program leaders as well as leaders of important CCSG and Institute initiatives [e.g., Imaging Development, Health Disparities]. The CCSG Steering Committee, chaired by Dr. Trump, provides a venue for strategic planning, program evaluation, membership review and approval and review of existing and proposed shared resources. Although there are several other venues where the Senior Leadership participates, it is through these two committees that primary decision-making is accomplished. There has been dramatic growth in RPCI during the last funding cycle. Over this funding cycle (2002 to 2006) the Senior Leadership team worked together to recruit more than 100 cancer investigators and clinicians, increase NCI funding by 74%, increase accruals to therapeutic investigator-initiated clinical trials and increase in out patient volume by 42% over this time period. As the number of cancer-focused basic, translational, clinical and population investigators at the RPCI have grown, four new Shared Resources have been established to support the needs of the membership with three more now in development. It is anticipated that the current Senior Leadership team will continue this successful trajectory via developing and executing longterm vision and strategic planning for the Institute.